New Releases


Warnex Medical Laboratories and Epigenomics announced this week that they are launching in Canada Warnex's Septin9 blood testing service for colorectal cancer.

Warnex's Septin9 test for the early detection of colorectal cancer is based on Epigenomics' biomarker Septin9 and its proprietary DNA methylation technologies. Warnex gained non-exclusive rights from Epigenomics for the Septin9 test in May, and will be the first laboratory to offer such testing in Canada.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.